Arrowhead Pharmaceuticals
ARWRAlgoritmens signaler
- ›Starkt 12m-momentum (+125.8%)
- ›Pris under både MA50 och MA200 (svag trend)
- ›Hög volatilitet (60% årlig)
- ›+127% från 52v-botten
- ›-31% från 52v-toppen
- ›Svagt 3m-momentum (-14.1%)
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsArrowhead Pharmaceuticals Plans Supplemental Drug Approval Application - Intellectia AI
10 h sedanArrowhead Pharmaceuticals Plans Supplemental Drug Approval Application Intellectia AI
Intellectia AIArrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 8.93% on Sep 15: What Investors Need To Know - tradingkey.com
1 d sedanArrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 8.93% on Sep 15: What Investors Need To Know tradingkey.com
tradingkey.comOne experimental therapy silenced two genes at once. More results will follow at a medical congress. - stocktitan.net
1 d sedanOne experimental therapy silenced two genes at once. More results will follow at a medical congress. stocktitan.net
stocktitan.netARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Stocktwits
2 d sedanARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval Stocktwits
StocktwitsArrowhead Pharmaceuticals (ARWR) Stock Looks Cheap On Cash Flow Yet Fair On Sales - simplywall.st
2026-09-05Arrowhead Pharmaceuticals (ARWR) Stock Looks Cheap On Cash Flow Yet Fair On Sales simplywall.st
simplywall.stCould Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? - finance.yahoo.com
2026-08-28Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? finance.yahoo.com
finance.yahoo.comArrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Arrowhead Pharmaceuticals, Inc.
2026-08-04Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? - Trefis
2026-07-23Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? Trefis
TrefisArrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
2025-11-18Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adju
Arrowhead PharmaceuticalsBusiness WireArrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
2025-11-06Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to discuss its financial results for the 2025 fisca
Arrowhead PharmaceuticalsBusiness WireArrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
2025-11-04Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: American Heart Association (AHA) Scientific Sessions 2025 – Novemb
Arrowhead PharmaceuticalsBusiness WireArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2025-10-28Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 24, 2025, the Company’s Board of Directors approved “induc
Arrowhead PharmaceuticalsBusiness WireArrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
2025-10-21Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announced on September 2, 2025, has now closed. Closing of
Arrowhead PharmaceuticalsBusiness WireArrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
2025-10-07Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigation
Arrowhead PharmaceuticalsBusiness WireArrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
2025-09-11Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ion
Arrowhead PharmaceuticalsBusiness WireArrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
2025-09-10Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational R
Arrowhead PharmaceuticalsBusiness Wire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.